A reversibly immortalized human β-cell line may find applications in diabetes therapy and drug screening.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Narushima, M. et al. Nat. Biotechnol. 23, 1274–1282 (2005).
Shapiro, A.M.J. et al. N. Engl. J. Med. 343, 230–238 (2000).
Colman, A. Sem. Cell Develop. Biol. 15, 337–345 (2004).
Ferber, S. et al. Nat. Med. 6, 568–572 (2000).
Zalzman, M. et al. Proc. Natl. Acad. Sci. USA 100, 7153–7258 (2003)
Gershengorn, M.C. Science 306, 2261–2264 (2004).
de la Tour, D.D. et al. Mol. Endocrinol. 15, 476–483 (2001).
Beattie, G.M. et al. Diabetes 51, 3435–3439 (2002).
Kulkarni Schmidt-Kastner, P.S., Heiden, T., Tribukait, B. & Grafstrom, R.C. Anticancer Res. 16, 2681–2686 (1996)
Hohmeier, H.E. & Newgard, C.B. Mol. Cell. Endocrinol. 228, 121–128 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hohmeier, H., Newgard, C. Islets for all?. Nat Biotechnol 23, 1231–1232 (2005). https://doi.org/10.1038/nbt1005-1231
Issue Date:
DOI: https://doi.org/10.1038/nbt1005-1231